Kiniksa Pharmaceuticals

KNSA · Nasdaq · Bermuda

Share price · KNSA

$95.05+15.56 (+19.57%) 3M

close as of 2026-11-18 · 24h delayed · vol 329K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KNSA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 27 Oct 2026+22.2%
  2. 26 Oct 2026-4.9%
  3. 23 Oct 2026-5.0%
  4. 28 Jul 2026+25.0%
  5. 28 Apr 2026+23.5%
  6. 20 Apr 2026-5.4%
  7. 8 Apr 2026-3.9%

    Nothing announced by KNSA that day or the session before.

  8. 24 Feb 2026-8.2%
  9. 19 Feb 2026+3.9%
  10. 16 Jan 2026+3.9%

    Nothing announced by KNSA that day or the session before.

Share of unusual movement by asset

For each asset, the share of KNSA's own-move activity since 15 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—38%
Sessions with no dated event—62%

No dated announcements about its assets since 15 Oct 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Oncostatin M receptor beta (OSMRβ)Monoclonal antibody
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
vixarelimabPhase 2Ulcerative Colitis
Est. primary completion 2027-08-25 · NCT06979336 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2025Topline resultvixarelimabVixarelimab Phase 2 MOONGLOW in ulcerative colitis stopped for futility
Genentech (Roche) · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$286M$33M$82M+ $487M short-term inv.—$48M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$244M$41M$176M+ $350M short-term inv.—$47M operating cash flowreport ↗
2026-Q1$214M$27M$190M+ $278M short-term inv.—$50M operating cash flowreport ↗
2025-Q3$181M$24M$175M+ $177M short-term inv.—$34M operating cash flowreport ↗
2025-Q2$157M$19M$192M+ $116M short-term inv.—$28M operating cash flowreport ↗
2025-Q1$138M$19M$157M+ $111M short-term inv.—$22M operating cash flowreport ↗
2024-Q3$112M$26M$97M+ $126M short-term inv.$13M-$2.2M operating cash flowreport ↗
2024-Q2$109M$24M$99M+ $119M short-term inv.$3.9M$5.2M operating cash flowreport ↗
2024-Q1$80M$26M$141M+ $72M short-term inv.$18M$4.0M operating cash flowreport ↗
2023-Q3$67M$17M$118M+ $83M short-term inv.$14M$17M operating cash flowreport ↗
2023-Q2$71M$24M$113M+ $72M short-term inv.—-$3.7M operating cash flowreport ↗
2023-Q1$48M$15M$81M+ $107M short-term inv.$12M-$4.3M operating cash flowreport ↗
2022-Q3$99M$16M$176M+ $25M short-term inv.—$62M operating cash flowreport ↗
2022-Q2$27M$14M$94M+ $44M short-term inv.$20M-$7.8M operating cash flowreport ↗
2022-Q1$32M$21M$63M+ $82M short-term inv.$25M-$37M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$678M$97M$166M+ $248M short-term inv.—$138M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$423M$112M$184M+ $60M short-term inv.$11M$26M operating cash flowreport ↗
2023-FY$270M$76M$108M+ $98M short-term inv.—$13M operating cash flowreport ↗
2022-FY$220M$65M$123M+ $68M short-term inv.—$5.8M operating cash flowreport ↗
2021-FY$39M$99M$122M+ $60M short-term inv.$39M-$126M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 87 sales ($121.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise29,670$10.36$307KForm 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise4,994$11.10$55KForm 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise3,723$11.97$45KForm 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise3,144$12.97$41KForm 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise2,595$15.52$40KForm 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise (derivative)29,670——Form 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise (derivative)4,994——Form 4
2026-11-13Paolini John F. · CHIEF MEDICAL OFFICEROption exercise (derivative)3,723——Form 4